Hepatoportal cholangiocarcinoma is a malignant tumor occurring in the hilar region of the liver, with jaundice as the main manifestation, and the expected survival is 6 months after diagnosis. The survival rate of 1, 3 and 5 years can reach 85%, 50% and 40% respectively for those who have completed the above steps of treatment.